US FDA Invites Randomized Trial Designs With Real-World Elements
Agency is eager to engage with sponsors on ‘well thought-out proposals' to include real-world data sources in randomized studies, Office of New Drugs director Peter Stein says but adds that believability and robustness of the data are the agency’s primary concern.
You may also be interested in...
Aduhelm Observational Study Will Spur Debate On Utility of Real-World Evidence For mABs In Alzheimer’s
Biogen’s ICARE AD-US study will assess the effects of aducanumab prescribed in routine practice to 6,000 patients. The lack of a concurrent control arm has critics questioning the study’s utility, but others say it could provide useful data on patient subgroups who were underrepresented or excluded from clinical trials and inform as to ARIA risks.
US FDA's Abernethy 'Cautious' About Real-World Evidence
FDA's principal deputy commissioner, who used to work in the real-world evidence field, said momentum is building, but more successful use cases are needed.
Real-World Evidence: When Is Missing Data Not Really 'Missing'?
The concept of missing data is very different when analyzing real-world evidence compared to a randomized clinical trial.